| Literature DB >> 32518266 |
Christophe Caneparo1, Clément Baratange1,2,3, Stéphane Chabaud4, Stéphane Bolduc5,6.
Abstract
Tissue engineering is an emerging and promising concept to replace or cure failing organs, but its clinical translation currently encounters issues due to the inability to quickly produce inexpensive thick tissues, which are necessary for many applications. To circumvent this problem, we postulate that cells secrete the optimal cocktail required to promote angiogenesis when they are placed in physiological conditions where their oxygen supply is reduced. Thus, dermal fibroblasts were cultivated under hypoxia (2% O2) to condition their cell culture medium. The potential of this conditioned medium was tested for human umbilical vein endothelial cell proliferation and for their ability to form capillary-like networks into fibrin gels. The medium conditioned by dermal fibroblasts under hypoxic conditions (DF-Hx) induced a more significant proliferation of endothelial cells compared to medium conditioned by dermal fibroblasts under normoxic conditions (DF-Nx). In essence, doubling time for endothelial cells in DF-Hx was reduced by 10.4% compared to DF-Nx after 1 week of conditioning, and by 20.3% after 2 weeks. The DF-Hx allowed the formation of more extended and more structured capillary-like networks than DF-Nx or commercially available medium, paving the way to further refinements.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32518266 PMCID: PMC7283357 DOI: 10.1038/s41598-020-66145-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Medium conditioned by dermal fibroblasts under hypoxic conditions increased the proliferation of human umbilical vein endothelial cells. Doubling time was calculated from growth curves determined after cell counts for unconditioned medium (DF medium, black dash line), medium conditioned by dermal fibroblasts under normoxic conditions (DF-Nx medium, solid black line) and medium conditioned by dermal fibroblasts under hypoxic conditions (DF-Hx medium, solid grey line). The periods of conditioning were 1, 2 or 3 weeks. Results are presented as average +/− standard deviation.
Figure 2Medium conditioned by dermal fibroblasts under hypoxic conditions allowed the formation of a highly structured capillary-like network by human umbilical vein endothelial cells. Representative microscope photographs taken on gels after human umbilical vein endothelial cells were cultivated with irradiated fibroblasts seeded in fibrin gels with unconditioned medium (DF medium, left upper panel), commercially available medium EGM-2MV (EGM-2MV, right upper panel), medium conditioned during 1 week by dermal fibroblasts under normoxic conditions (DF-Nx medium, left lower panel) and medium conditioned during 1 week by dermal fibroblasts under hypoxic conditions (DF-Hx medium, right lower panel). Whereas no structures could be observed for DF medium and DF-Nx, capillary-like structures were visible for EGM-2MV and DF-Hx conditions. The network was more elaborated with DF-Hx. Tubulogenesis could be observed with the inner vacuole, which formed the lumen.
Figure 3Increasing the duration of the conditioning period did not increase the number of capillary-like structures. Representative microscope photographs taken on gels after human umbilical vein endothelial cells were cultivated with irradiated fibroblasts seeded in fibrin gels with medium conditioned by dermal fibroblasts under hypoxic conditions during 1 week (upper panels) or 2 weeks (lower panels). Despite a more extended period of conditioning, the 2 weeks-condition did not promote a higher number of structures. It is possible that fewer structures were present in this latter condition, but the 3D context did not allow a precise determination of such parameters using brightfield microscopy. Once again, tubulogenesis was visible with the inner vacuole forming the lumen.
Figure 4Medium conditioned by dermal fibroblasts under hypoxic conditions allowed the formation of a CD-31 positive, highly structured capillary-like network by human umbilical vein endothelial cells. Representative fluorescent microscope photographs taken on CD-31 immuno-labelled gels after human umbilical vein endothelial cells were cultivated with irradiated fibroblasts seeded in fibrin gels with unconditioned medium (DF medium, left upper panel), medium conditioned during 1 week by dermal fibroblasts under normoxic conditions (DF-Nx medium, central upper panel), commercially available medium EGM-2MV (EGM-2MV, right upper panel), and medium conditioned during 1 week by dermal fibroblasts under hypoxic conditions (DF-Hx medium, lower panels). No structures could be seen in DF medium condition and few ones in the DF-Nx condition. EGM-2MV condition showed several structures but with a reduced degree of maturation compared to what was obtained using DF-Hx.
Figure 5Quantification of length and branching number of capillary-like structures observed in fibrin gels. the CD-31 immuno-labelling, length and branching number of the capillary-like structures were measured for conditions using commercially available medium EGM-2MV (EGM-2MV), unconditioned medium (DF medium), medium conditioned during 1 week by dermal fibroblasts under normoxic conditions (DF-Nx), and medium conditioned during 1 week by dermal fibroblasts under hypoxic conditions (DF-Hx). (A) Quantification of the length of the structures. N is the number of observed structures in the central field of 3 distinct gels. The length was expressed as the value provided by ImageJ software. (B) Comparison of the total length of capillary-like structures and their branching number.
Figure 6Determination of the angiogenic profile of DF-Nx medium (1 week) and DF-Hx medium (1 week) using a commercially available macro-array. The medium conditioned during 1 week by dermal fibroblasts under normoxic conditions (DF-Nx), and medium conditioned during 1 week by dermal fibroblasts under hypoxic conditions (DF-Hx) used to test the proliferation of HUVEC and the proangiogenic potential in fibrin gels were assayed in triplicate on human angiogenesis antibody arrays C1000 from RayBiotech. (A) The array is divided into two membranes (one represented in the left upper panel, the other in the left lower panel). Proteins detected by the array are indicated on the representation. Representative membranes were shown for DF-Nx medium (center panels) and DF-Hx medium (right panels). (B) Results were normalized to the positive control present on each membrane after subtraction of the background. The expression of each protein was compared to the expression of this protein in the DF-Nx condition. Values are average +/− standard deviation.
Protein expression values from human angiogenesis antibody arrays.
| Fold increase | DF-Nx | sd (+/−) | DF-Hx | sd (+/−) | p value | |
|---|---|---|---|---|---|---|
| EGF | 8,86 | 0,0056 | 0,0015 | 0,0496 | 0,0031 | 0,0000 |
| Leptin | 5,86 | 0,0722 | 0,0187 | 0,4231 | 0,0416 | 0,0000 |
| GM-CSF | 4,55 | 0,0047 | 0,0002 | 0,0214 | 0,0022 | 0,0092 |
| CXCL5 | 2,84 | 0,0637 | 0,0135 | 0,1808 | 0,0114 | 0,0000 |
| bFGF | 2,67 | 0,0276 | 0,0017 | 0,0735 | 0,0187 | 0,0015 |
| PlGF | 2,24 | 0,0423 | 0,0116 | 0,0949 | 0,0138 | 0,3007 |
| IGF-1 | 1,99 | 0,0248 | 0,0043 | 0,0493 | 0,0024 | 0,0006 |
| IL-4 | 1,71 | 0,0103 | 0,0011 | 0,0176 | 0,0000 | 0,2228 |
| MCP-3 (CCL7) | 1,55 | 0,1307 | 0,0188 | 0,2030 | 0,0419 | 0,0046 |
| IL8 | 1,37 | 1,6092 | 0,0740 | 2,2012 | 0,1658 | 0,0001 |
| CXCL123 | 1,3 | 3,3623 | 0,1755 | 4,3644 | 0,2529 | 0,0000 |
| TIMP-1 | 1,26 | 0,4689 | 0,0361 | 0,5891 | 0,0227 | 0,1068 |
| IL6 | 1,23 | 3,9071 | 0,0814 | 4,8150 | 0,0198 | 0,0000 |
| MMP-1 | 1,07 | 0,3044 | 0,0246 | 0,3248 | 0,0202 | 0,3956 |
| Angiogenin | 1,02 | 0,2275 | 0,0021 | 0,2331 | 0,0231 | 0,2815 |
| VEGF-A | 1 | 0,2473 | 0,0183 | 0,2472 | 0,0329 | 0,9957 |
| MCP-1 | 0,99 | 0,6679 | 0,0531 | 0,6587 | 0,0389 | 0,7606 |
| Endostatin | 0,93 | 0,0404 | 0,0095 | 0,0378 | 0,0034 | 0,3101 |
| TIMP-2 | 0,92 | 0,5669 | 0,0768 | 0,5220 | 0,0881 | 0,4361 |
| Angiostatin | 0,9 | 0,0472 | 0,0036 | 0,0426 | 0,0038 | 0,2252 |
| I-309 (CCL1) | 0,9 | 0,0171 | 0,0018 | 0,0154 | 0,0007 | 0,2836 |
| IFNg | 0,86 | 0,0354 | 0,0005 | 0,0303 | 0,0105 | 0,5991 |
| uPAR | 0,82 | 0,3223 | 0,0135 | 0,2662 | 0,0439 | 0,0221 |
| TGFb1 | 0,81 | 0,0388 | 0,0030 | 0,0313 | 0,0048 | 0,2851 |
| I-TAC (CXCL11) | 0,81 | 0,0251 | 0,0030 | 0,0204 | 0,0028 | 0,0817 |
| CCL5 | 0,8 | 0,0503 | 0,0108 | 0,0403 | 0,0058 | 0,9431 |
| IL-1 alpha | 0,8 | 0,0424 | 0,0016 | 0,0339 | 0,0042 | 0,0059 |
| VEGF R2 | 0,79 | 0,0163 | 0,0008 | 0,0129 | 0,0004 | 0,1818 |
| VEGF R3 | 0,77 | 0,0336 | 0,0067 | 0,0259 | 0,0042 | 0,2033 |
| MCP-4(CCL 13) | 0,76 | 0,0373 | 0,0011 | 0,0284 | 0,0027 | 0,0267 |
| IL-1 beta | 0,75 | 0,0294 | 0,0034 | 0,0222 | 0,0032 | 0,0132 |
| Tie-2 | 0,72 | 0,0441 | 0,0009 | 0,0316 | 0,0038 | 0,0008 |
| IL-10 | 0,71 | 0,0080 | 0,0009 | 0,0057 | 0,0016 | 0,1188 |
| MMP-9 | 0,64 | 0,0399 | 0,0025 | 0,0254 | 0,0024 | 0,0059 |
| TPO | 0,61 | 0,1117 | 0,0080 | 0,0679 | 0,0056 | 0,0387 |
| ANGPT2 | 0,6 | 0,3570 | 0,0373 | 0,2132 | 0,0269 | 0,0000 |
| PECAM-1 (CD31) | 0,55 | 0,0262 | 0,0002 | 0,0144 | 0,0019 | 0,0000 |
| ANGPT1 | 0,53 | 0,4156 | 0,0420 | 0,2189 | 0,0083 | 0,0028 |
| PDGF-BB | 0,3 | 0,0108 | 0,0000 | 0,0032 | 0,0009 | 0,3960 |
| VEGF-D | 0,21 | 0,0303 | 0,0000 | 0,0064 | 0,0010 | 0,0085 |
As the calculation of the ratio did not allow an estimation of the corresponding amount of each protein, protein expression value normalized to the positive control present on each membrane after subtraction of the background was presented in Table 1. First column: name of the protein, second column: the ratio between signals obtained in DF-Hx condition vs DF-Nx condition. Third column: average value for DF-Nx condition, fourth column: standard deviation for DF-Nx condition, fifth column: average value for DF-Hx condition, sixth column: standard deviation for DF-Hx condition, seventh and last column: p-value using a student t-test between average values from DF-Nx and DF-Hx conditions. Epidermal growth factor (EGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), chemokine (C-X-C motif) ligand (CXCL), basic fibroblast growth factor (bFGF), insulin-like growth factor 1 (IGF-1), monocyte chemoattractant protein(MCP), interleukin-8 (IL-8), Placental growth factor, (PlGF), tissue inhibitors of metalloproteinases (TIMP), Matrix metalloproteinase-1 (MMP-1), vascular endothelial growth factor (VEGF), chemokine (C-C motif) ligand (CCL), Interferon-γ (IFNγ), transforming growth factor-β1 (TGF-β1), VEGF receptor (VEGFR), platelet-derived growth factor-BB (PDGF-BB), Urokinase-type plasminogen activator receptor (uPAR), angiopoietin-1 receptor (Tie2), thrombopoietin (TPO), cluster of differentiation-31 (CD-31).